Leukocytoclastic vasculitis is an inflammatory disease of the small blood vessels that most often shows itself as a palpable purpuric rash on the legs. Many things can trigger it, but medications are an under-recognised cause. This is a case from our practice of probable amiodarone-induced disease, in which a common cardiac drug was the favoured culprit and a simple temporal observation made the diagnosis.
Case presentation
63-year-old woman — new rash, fatigue and malaise
Presented to her GP with one week of severe fatigue, malaise, low-grade fever, generalised aches and a non-pruritic rash, most marked on the lower legs.
She denied chest pain, dyspnoea, overt bleeding or melaena. Initially the weakness was severe enough to stop her performing simple daily tasks or attending work, and the rash on her legs was florid.
Four weeks earlier she had been hospitalised with atrial fibrillation and a rapid ventricular rate. She underwent three unsuccessful DC cardioversions before reverting to sinus rhythm after amiodarone was started with a loading dose. She was discharged in sinus rhythm on a tapering dose of amiodarone, metoprolol 50 mg twice daily and rivaroxaban 20 mg daily — the latter continued from her established atrial fibrillation therapy.
Suspecting that amiodarone — her newest medication — might be responsible, the patient reduced her own dose to 100 mg daily and then stopped it for several days before seeing her GP. Over that period her symptoms, including the rash, improved noticeably. This unplanned, drug-specific dechallenge would prove central to the diagnosis.
Background and medications
Her history included well-controlled ulcerative colitis, a non-ST-elevation myocardial infarction treated with angioplasty five years earlier, hypertension and paroxysmal atrial fibrillation. She smoked ten cigarettes daily and worked in a warehouse.
Amiodarone was the only medication newly introduced around the onset of her illness; her other agents — including rivaroxaban — had been part of her regimen since her atrial fibrillation was diagnosed.
| Medication | Status at presentation |
|---|---|
| Amiodarone | Newly started — loaded four weeks earlier, then tapering |
| Rivaroxaban 20 mg daily | Long-standing (since AF diagnosis); continued |
| Metoprolol 50 mg twice daily | Long-standing; continued |
| Perindopril 5 mg daily | Long-standing |
| Atorvastatin | Long-standing |
| Aspirin 100 mg daily | Long-standing |
| Sulfasalazine 500 mg twice daily | Long-standing (ulcerative colitis) |
Examination findings
On examination her blood pressure was 130/80 mmHg with a regular pulse of 75 bpm, and her cardiorespiratory examination was unremarkable. She had a widespread papular, non-blanching rash with petechiae, most prominent on the legs.
Investigations and biopsy
Renal and liver function were normal, with a mild inflammatory picture on bloods.
| Test | Result | Comment |
|---|---|---|
| Haemoglobin | 178 g/L | Raised; possible smoking-related erythrocytosis or haemoconcentration |
| White cell count | 15.6 × 109/L | Raised |
| Platelets | 475 × 109/L | Mild thrombocytosis, likely reactive |
| CRP | 66 mg/L | Raised |
| ESR | 42 mm/hr | Raised |
| TSH, HbA1c, lipids | Normal | — |
There was no clinical evidence of systemic involvement. In suspected leukocytoclastic vasculitis, urinalysis is an important part of the systemic screen, as it can detect renal involvement that would change management.
A skin biopsy confirmed small-vessel vasculitis with the histological features of leukocytoclastic vasculitis. She developed no systemic complications, and after amiodarone was withdrawn and a short course of corticosteroid given, she made a complete recovery.
What is leukocytoclastic vasculitis?
Leukocytoclastic vasculitis is a histopathological term for a common form of small-vessel vasculitis, in which neutrophils inflame and damage the walls of small vessels — particularly the post-capillary venules of the skin. “Leukocytoclasia” refers to the fragmentation of those neutrophils; the released nuclear debris drives further inflammation and vessel-wall injury. In the Chapel Hill consensus nomenclature, skin-limited disease sits among the single-organ vasculitides.
Clinically it usually presents as palpable purpura on the lower limbs, sometimes with fever, malaise and arthralgia. It is best understood as an immune-complex-mediated reaction and can be triggered by medications, infections, autoimmune or connective-tissue disease, or malignancy — or be idiopathic. The first task is always to decide whether the process is skin-limited or the visible tip of a systemic vasculitis.
Why suspect a drug — and why amiodarone?
The single most useful clue to drug-induced cutaneous vasculitis is timing: the rash typically appears 7–21 days after first exposure to a drug or infectious trigger, and settles once the trigger is removed. In this patient the rash began within weeks of starting amiodarone and resolved as it was withdrawn — a textbook temporal correlation.
Amiodarone was the only medication newly introduced around the onset of her illness; rivaroxaban, metoprolol and her other drugs had been part of her regimen since her atrial fibrillation was diagnosed. DOAC-associated leukocytoclastic vasculitis has been reported, so a newly started anticoagulant would have warranted consideration — but here the anticoagulant was long-standing. The most persuasive clue favouring amiodarone was a drug-specific dechallenge: she reduced and then stopped amiodarone while continuing the rest of her regimen, with noticeable improvement. In the absence of a deliberate rechallenge, this is best regarded as probable amiodarone-induced disease.
Amiodarone-induced leukocytoclastic vasculitis remains rare, with only a small number of reported cases, and is probably under-recognised given how widely the drug is used. A near-identical case was published in 2024: a patient hospitalised with atrial fibrillation and a rapid ventricular rate, started on amiodarone, who then developed biopsy-proven disease. The pattern in our patient — onset after amiodarone, resolution on withdrawal — fits the same mechanism.
Management
In drug-induced leukocytoclastic vasculitis the priority is to identify and stop the suspected culprit. Where the disease is skin-limited and the trigger is removed, the prognosis is favourable and the rash often settles with withdrawal alone.
The next step is to exclude systemic involvement — particularly renal disease — since this determines how far treatment needs to escalate. A baseline systemic screen, including urinalysis, helps separate skin-limited disease from a systemic vasculitis.
For symptomatic or more extensive skin disease, a short course of low-dose corticosteroid helps control symptoms and should be tapered rather than stopped abruptly. Supportive measures — rest, leg elevation and avoiding prolonged standing — are worthwhile, and colchicine (0.5 mg twice daily) or dapsone are reasonable options for relapsing skin-limited disease. Escalation to agents such as rituximab or cyclophosphamide is not part of routine management for isolated drug-induced cutaneous disease; those are reserved for organ-threatening or systemic vasculitis after specialist assessment.
- Amiodarone is a rare but recognised cause of leukocytoclastic vasculitis; suspect it when a purpuric rash appears after the drug is started.
- Timing is the key diagnostic clue — cutaneous drug reactions typically begin 7–21 days after exposure and resolve on withdrawal.
- When the medication history is complex, a drug-specific dechallenge can point to the most probable culprit.
- Always decide whether the disease is skin-limited or systemic, and exclude renal involvement.
- For drug-induced, skin-limited disease, stopping the culprit is the cornerstone — the prognosis is good and aggressive immunosuppression is rarely needed.
Frequently asked questions
What is leukocytoclastic vasculitis?
It is a form of small-vessel vasculitis in which neutrophils inflame and damage the walls of small skin vessels. It usually appears as a palpable purpuric rash on the lower legs and is diagnosed on skin biopsy.
Can amiodarone really cause a skin vasculitis?
Yes, though it is uncommon and probably under-recognised. The clue is a purpuric rash that develops after the drug is started and improves once it is stopped.
How is drug-induced leukocytoclastic vasculitis diagnosed?
By combining the clinical picture, a skin biopsy showing leukocytoclastic vasculitis, and the timing — onset after starting a drug and improvement on stopping it (a “dechallenge”). Other causes such as infection, autoimmune disease and systemic vasculitis are excluded.
How is it treated?
The main step is stopping the responsible drug, which alone often resolves skin-limited disease. A short corticosteroid course can settle symptoms, and colchicine or dapsone are used for relapsing skin-limited disease. Aggressive immunosuppression is reserved for systemic vasculitis, not isolated drug-induced skin disease.
Will it come back?
Drug-induced disease usually does not recur once the culprit is avoided. Re-exposure to the same drug can trigger a faster and sometimes more severe reaction, so the drug is generally avoided in future.
References and further reading
Amiodarone and drug-induced vasculitis
- Asfeen U, et al. Amiodarone-induced leukocytoclastic vasculitis in a decompensated heart failure patient: a case report. Cureus. 2024;16(1):e51817.
- Ak T, et al. Amiodarone-induced cutaneous leukocytoclastic vasculitis: a case report and review of the literature. Clin Rheumatol. 2022;41(9):2875–2881.
- Ndiaye M, et al. Amiodarone-induced immune complex cutaneous vasculitis. Ann Dermatol Venereol. 2017;144(12):788–792.
- Yaseen K, Nevares A, Tamaki H. A spotlight on drug-induced vasculitis. Curr Rheumatol Rep. 2022;24(11):323–336.
Leukocytoclastic vasculitis — diagnosis and management
- Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021;16(4):831–841.
Managing a patient with a complex cardiac history?
Heartcare Sydney provides consultant cardiology assessment in Westmead and St Leonards, including arrhythmia management and preventive cardiology.
Refer a patient